Major Depressive Disorder

Check out new positive topline data from the SAVITRI study assessing the efficacy and safety of NBI-1065845 in adults with major depressive disorder.

Here are highlights from the week in Psychiatric Times.

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of a new phase 3 study.

From a look at record-high suicide rates to subspecialty shortages in psychiatry, here are highlights from the week in Psychiatric Times.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

New phase 2 study initiated to determine the potential of ALTO-203 as an antidepressant in patients with major depressive disorder and anhedonia.

The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of March.

Here’s a look back at selections from our March content series on mood disorders.

Our March CME reviews the principles and applications of invasive and noninvasive neuromodulation techniques for the treatment of mood disorders. Here are 5 key takeaways.

This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.

From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

In this CME article, review the principles and applications of both invasive and noninvasive neuromodulation techniques for the treatment of mood disorders.

Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.

Given that two-thirds of patients treated for a major depressive episode will fail to achieve remission of symptoms after 2 or more treatment trials of first-line antidepressants, the probability of remission will further decrease with subsequent medication trials. Treatment strategies for patients with TRD include augmentation, where a medication is added to a current antidepressant versus switching to a different antidepressant.

The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.

Take a look back at our recent coverage relating to our March content theme.

From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.

New research on transcranial direct current stimulation effectiveness in treating major depressive disorder.

The original STAR*D authors refute claims of a violated protocol.